Published: 24 July 2026 | 6.00 AM
Last Updated: 24 July 2026 | 3.00 PM
Manipal Health Enterprises IPO Snapshot
| Particulars | Details |
|---|---|
| Chanakya View | 🟡 Selective Apply |
| Overall Rating | ⭐⭐⭐⭐☆ (3.8/5) |
| GMP Today | Rs. 25 frequently updated |
| Issue Size | Approximately Rs. 9,210–9,275 Crore |
| Fresh Issue | Up to Rs. 8,000 Crore |
| Offer for Sale | Up to 2,16,13,834 Shares |
| Price Band | Rs. 560–Rs. 590 |
| Face Value | Rs. 2 per Share |
| Lot Size | 25 Shares |
| Minimum Retail Investment | Rs. 14,750 |
| IPO Opens | 29 July 2026 |
| IPO Closes | 31 July 2026 |
| Anchor Bidding | 28 July 2026 |
| Basis of Allotment | 3 August 2026 |
| Refunds/Unblocking | 4 August 2026 |
| Shares Credited | 4 August 2026 |
| Listing Date | 5 August 2026 |
| Exchange | BSE and NSE |
| Employee Discount | Rs. 56 per Share |
| Registrar | KFin Technologies Ltd. |
Manipal Health’s original DRHP was filed in March 2026, and SEBI subsequently cleared the proposed public offer in early July. The final issue retains a fresh issue of up to Rs. 8,000 crore but has reduced the OFS compared with the draft offer.
Investor Decision Box
| Question | Chanakya View |
|---|---|
| Suitable for Listing Gain? | 🟡 Yes, subject to GMP and QIB demand |
| Suitable for Long-Term? | 🟢 Yes, but valuation is expensive |
| Risk Level | Medium |
| Business Quality | ⭐⭐⭐⭐⭐ |
| Financial Strength | ⭐⭐⭐⭐☆ |
| Balance Sheet | ⭐⭐⭐☆☆ |
| Growth Potential | ⭐⭐⭐⭐☆ |
| Valuation Comfort | ⭐⭐☆☆☆ |
Chanakya View
Manipal Health Enterprises offers investors an opportunity to participate in one of India’s largest multispecialty hospital networks. The company has a strong brand, a pan-India presence, leadership in major metropolitan markets and a large base of hospitals, beds, doctors and specialised medical services.
The strongest aspect of the IPO is the proposed use of fresh capital. Approximately Rs. 5,378 crore is intended for repayment or prepayment of borrowings of Manipal Hospitals Private Limited, while Rs. 574 crore will be used to acquire a minority stake in Sahyadri Hospitals. Debt reduction should lower finance costs, strengthen the consolidated balance sheet and improve future earnings quality.
However, the valuation is demanding. At the upper price band, the post-issue market capitalisation is estimated at approximately Rs. 77,607 crore. Based on FY25 pro forma PAT of Rs. 534.80 crore, the IPO is valued at roughly 145 times earnings. Even after annualising the six-month profit reported for September 2025, the valuation remains above 120 times earnings.
The company’s scale and long-term healthcare opportunity justify a premium valuation, but the offer leaves limited room for operational disappointment. Therefore, the IPO is suitable for selective investors rather than those seeking a low-risk value opportunity.
Chanakya Recommendation: 🟡 Selective Apply
The final decision for listing gains should depend on GMP, institutional subscription and overall market conditions during 29–31 July.
About Manipal Health Enterprises
Manipal Health Enterprises Limited is a major healthcare services provider operating multispecialty hospitals, clinics and diagnostic facilities. It forms part of the Manipal Group, whose healthcare and education legacy is associated with founder T. M. A. Pai.
The company provides tertiary and quaternary medical services across areas such as oncology, cardiology, neurosciences, orthopaedics, organ transplantation, critical care, renal sciences and preventive healthcare.
As of 30 September 2025, the company operated 38 hospitals with 10,761 licensed beds. On a pro forma basis, including relevant acquisitions and expansions, the network comprised 48 hospitals and 12,367 licensed beds. The company also operated 17 clinics.
Manipal describes itself as India’s largest multispecialty hospital group by bed capacity, with leadership positions in Bengaluru, Kolkata and Pune. Its diversified network includes both metropolitan and non-metropolitan markets, reducing dependence on any single city or region.
Why Manipal Health Enterprises IPO Stands Out
✅ One of India’s largest multispecialty hospital networks by bed capacity.
✅ Leadership in three important healthcare markets—Bengaluru, Kolkata and Pune.
✅ Strong presence across tertiary and quaternary healthcare specialities.
✅ Recognised brand among patients, doctors and medical professionals.
✅ Fresh capital will substantially reduce group borrowings.
✅ Acquisition of the minority stake in Sahyadri Hospitals can simplify ownership and strengthen the Pune and Maharashtra network.
✅ EBITDA margins have remained healthy at more than 26%.
✅ India’s demand for organised hospital care continues to benefit from rising incomes, insurance penetration, ageing demographics and increased incidence of lifestyle diseases.
Key Risks
⚠ The IPO valuation is expensive based on reported FY25 earnings.
⚠ Hospital operations require significant investment in land, buildings, equipment, doctors and technology.
⚠ Profitability can be affected by delays in ramping up newly acquired or newly opened hospitals.
⚠ The business depends heavily on retaining experienced doctors and specialised medical professionals.
⚠ Regulatory changes affecting hospital pricing, medical devices or insurance reimbursements may affect margins.
⚠ Acquisitions increase integration risk and may temporarily affect profitability.
⚠ A large issue size requires strong institutional participation for successful price discovery.
⚠ Recent hospital-sector IPOs have delivered mixed listing-day performance, indicating that business quality alone does not guarantee listing gains.
Financial Snapshot – Pro Forma Consolidated
| Particulars | H1 FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Total Income | Rs. 5,436.31 Cr | Rs. 9,409.12 Cr | Rs. 6,265.17 Cr | Rs. 4,927.57 Cr |
| EBITDA | Rs. 1,439.15 Cr | Rs. 2,455.03 Cr | Rs. 1,596.98 Cr | Rs. 1,228.24 Cr |
| Profit After Tax | Rs. 319.47 Cr | Rs. 534.80 Cr | Rs. 533.20 Cr | Rs. 414.20 Cr |
| Assets | Rs. 22,579.11 Cr | Rs. 21,443.81 Cr | Rs. 10,818.83 Cr | Rs. 7,936.78 Cr |
| Net Worth | Not Disclosed | Not Disclosed | Rs. 4,029.22 Cr | Rs. 3,325.29 Cr |
Chanakya Financial Interpretation
Manipal Health reported strong expansion in its operating scale. FY25 total income increased by approximately 50% to Rs. 9,409.12 crore, primarily reflecting acquisitions and network consolidation. EBITDA rose to Rs. 2,455.03 crore, while the EBITDA margin remained healthy at approximately 26.1%.
Profit after tax, however, remained nearly flat at Rs. 534.80 crore compared with Rs. 533.20 crore in FY24. This suggests that higher depreciation, interest costs, acquisition-related expenses or other non-operating factors absorbed a meaningful part of the operating growth.
The six-month period ended September 2025 showed improvement, with PAT reaching Rs. 319.47 crore and EBITDA margin rising to approximately 28%. The proposed debt repayment could support stronger profit conversion after the IPO.
Key Performance Indicators
| KPI | September 2025 | March 2025 |
|---|---|---|
| Return on Net Worth | 8.72% | 18.16% |
| PAT Margin | 6.01% | 5.77% |
| EBITDA Margin | 27.99% | 26.65% |
| ROCE | Not Available | 26.98% |
The operating margin is strong for a large hospital network. However, the decline in RoNW requires attention, particularly because the post-issue equity base will expand further following the fresh issue.
Valuation Analysis
| Valuation Parameter | Estimate |
|---|---|
| Upper Price Band | Rs. 590 |
| Post-Issue Market Capitalisation | Approximately Rs. 77,607 Crore |
| FY25 PAT | Rs. 534.80 Crore |
| Approximate FY25 P/E | Around 145x |
| Annualised H1 FY26 PAT | Approximately Rs. 638.94 Crore |
| Approximate Annualised P/E | Around 121x |
| FY25 Market Cap-to-Sales | Around 8.2x |
The valuation is the IPO’s principal concern. Manipal Health may command a premium because of its network, brand, specialised care capabilities and growth prospects. Nevertheless, a P/E above 120 times annualised earnings requires continued improvement in occupancy, average revenue per occupied bed, margins and finance costs.
Investors should not treat the IPO as inexpensive merely because the minimum retail application is only Rs. 14,750.
Business Quality Score
| Parameter | Rating |
|---|---|
| Business Model | ⭐⭐⭐⭐⭐ |
| Brand Strength | ⭐⭐⭐⭐⭐ |
| Industry Outlook | ⭐⭐⭐⭐☆ |
| Financial Performance | ⭐⭐⭐⭐☆ |
| Management and Network | ⭐⭐⭐⭐☆ |
| Balance Sheet | ⭐⭐⭐☆☆ |
| Growth Potential | ⭐⭐⭐⭐☆ |
| Valuation | ⭐⭐☆☆☆ |
IPO Proceeds and Why They Matter
| Purpose | Estimated Amount |
|---|---|
| Repayment or Prepayment of Borrowings and Accrued Interest of Manipal Hospitals Private Limited | Rs. 5,378 Crore |
| Acquisition of Minority Stake in Sahyadri Hospitals Private Limited | Rs. 574 Crore |
| General Corporate Purposes | Balance Amount |
Debt repayment is the most important positive trigger in this IPO. A reduction of Rs. 5,378 crore in borrowings could lower annual interest expenditure, strengthen cash flows and improve the proportion of EBITDA converted into profit after tax.
The Sahyadri Hospitals transaction may enable Manipal to increase control over an important regional hospital platform. It could also improve strategic integration, branding, doctor engagement and capital allocation within the group.
Unlike an IPO primarily funding new hospitals, the immediate benefit may appear more prominently through balance-sheet improvement and lower finance costs rather than a sudden increase in bed capacity.
Issue Structure and Reservation
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers | 75% |
| Non-Institutional Investors | 15% |
| Retail Investors | 10% |
| Employee Reservation | Shares aggregating up to Rs. 15 Crore |
| Employee Discount | Rs. 56 per Share |
The allocation differs from the standard 50%-QIB structure mentioned at the DRHP stage. Under the final issue advertisement, 75% of the offer is allocated to QIBs, 15% to NIIs and only 10% to retail investors.
At the upper price band, approximately 6,27,811 retail applications may receive one lot if the retail portion is subscribed exactly one time. The number of available retail allotments is therefore meaningful, though oversubscription can still reduce the probability substantially.
Application Details
| Category | Minimum Shares | Minimum Amount at Rs. 590 |
|---|---|---|
| Retail | 25 Shares | Rs. 14,750 |
| Small NII | 350 Shares | Rs. 2,06,500 |
| Big NII | 1,700 Shares | Rs. 10,03,000 |
Retail investors can apply in multiples of 25 shares. The employee discount of Rs. 56 per share reduces the effective upper-band price for eligible employees to Rs. 534 per share.
Business Outlook
India’s organised hospital industry has several structural growth drivers, including increasing health insurance coverage, growth in medical tourism, rising household incomes, ageing demographics and higher prevalence of cancer, cardiovascular ailments, diabetes and other chronic conditions.
Large hospital chains also benefit from brand recognition, access to specialist doctors, procurement scale, advanced medical equipment and the ability to spread central administrative costs across a larger network.
Manipal Health is well positioned to participate in this opportunity because of its presence in major cities and its broad speciality mix. The company can generate further growth through improved occupancy, price increases, better case mix, operational turnaround of acquired hospitals and selective expansion.
However, hospitals generally require a long gestation period. New facilities may incur losses during the initial years, while acquisitions can involve integration challenges. Growth must therefore be evaluated alongside return on capital and cash-flow generation.
Strengths vs Concerns
| 👍 Strengths | ⚠ Concerns |
|---|---|
| Leading hospital network by bed capacity | Expensive IPO valuation |
| Strong presence in Bengaluru, Kolkata and Pune | FY25 PAT remained nearly flat |
| Recognised Manipal brand | Capital-intensive operations |
| Healthy EBITDA margins | Integration risk from acquisitions |
| Debt repayment from IPO proceeds | Dependence on specialist doctors |
| Diversified speciality portfolio | Regulatory and pricing risks |
| Pan-India network | Large issue requires strong QIB demand |
Who Should Apply?
| Investor Type | Suitability |
|---|---|
| Listing Gain Investors | ⭐⭐⭐☆☆ |
| Long-Term Growth Investors | ⭐⭐⭐⭐☆ |
| Conservative Investors | ⭐⭐☆☆☆ |
| Healthcare-Sector Investors | ⭐⭐⭐⭐☆ |
| Valuation-Conscious Investors | ⭐⭐☆☆☆ |
| High-Risk Investors | ⭐⭐⭐⭐☆ |
Chanakya View for Different Investors
Listing gain investors should monitor GMP after reliable grey-market trading begins. The issue’s size and premium valuation make QIB subscription particularly important. A healthy GMP supported by strong institutional demand would improve the listing outlook.
Long-term investors may consider applying selectively because Manipal Health has a high-quality business, substantial scale and favourable industry prospects. However, investors must be prepared for valuation-related volatility after listing.
Conservative investors may wait for post-listing price discovery. Even a strong company can deliver modest or negative returns when the IPO valuation discounts several years of future growth.
Listing Gain Potential
| Factor | Assessment |
|---|---|
| Brand Recognition | Strong |
| Institutional Appeal | Strong |
| Issue Size | Very Large |
| Valuation | Expensive |
| Sector Sentiment | Positive |
| Recent Hospital IPO Listings | Mixed |
| GMP Signal | Awaited |
| Current Listing Gain Probability | Moderate |
The listing-gain outlook cannot be finalised until GMP and subscription data become available. The IPO’s healthcare brand and institutional positioning are positives, but its large size and elevated valuation may restrict excessive listing premiums.
Long-Term Potential
Manipal Health offers good long-term business potential because organised hospital capacity in India remains inadequate relative to demand. Its existing network provides a platform for operating leverage, cross-referrals, central procurement and expansion of high-value medical specialities.
Debt reduction could materially improve the company’s earnings profile. If Manipal maintains its EBITDA margin while reducing finance costs, profit growth may become stronger than revenue growth over the next few years.
The principal risk is that the IPO already prices in a large part of this expected improvement. Long-term returns will therefore depend not only on business growth but also on whether the company can grow into its initial valuation.
Chanakya Final Verdict
Manipal Health Enterprises is a high-quality healthcare company with a recognised brand, one of India’s largest hospital networks and leadership in several important regional markets. Its scale, clinical capabilities and diversified presence create a strong platform for long-term growth.
The IPO’s use of proceeds is favourable. Repayment of approximately Rs. 5,378 crore of subsidiary debt can reduce finance costs and strengthen the balance sheet, while the acquisition of the minority stake in Sahyadri Hospitals can simplify the group structure and support regional growth.
However, the IPO is offered at a steep valuation of around 145 times FY25 earnings and more than 120 times annualised H1 FY26 earnings. This valuation reduces the margin of safety and raises the risk of post-listing volatility if earnings growth falls short of expectations.
Chanakya Recommendation: 🟡 Selective Apply
Apply for listing gains only if GMP remains healthy and QIB subscription is strong. Long-term investors with a three-to-five-year horizon may apply selectively, while conservative and valuation-conscious investors may wait for post-listing price discovery.
Frequently Asked Questions
What is the Manipal Health Enterprises IPO?
The Manipal Health Enterprises IPO is a mainboard book-built issue consisting of a fresh issue of up to Rs. 8,000 crore and an OFS of up to 2,16,13,834 equity shares.
What is the price band of the Manipal Health Enterprises IPO?
The Manipal Health Enterprises IPO price band is Rs. 560 to Rs. 590 per share.
What is the minimum investment in the Manipal Health Enterprises IPO?
Retail investors must apply for at least 25 shares. The minimum investment at the upper price band is Rs. 14,750.
When will the Manipal Health Enterprises IPO open?
The IPO opens on 29 July 2026 and closes on 31 July 2026. Anchor investor bidding is scheduled for 28 July 2026.
When will Manipal Health Enterprises shares list?
The shares are expected to list on BSE and NSE on 5 August 2026, subject to the completion of the allotment and listing process.
How will Manipal Health Enterprises use the IPO proceeds?
Approximately Rs. 5,378 crore will be used to repay borrowings of Manipal Hospitals Private Limited, and Rs. 574 crore will fund the acquisition of a minority stake in Sahyadri Hospitals. The balance will be used for general corporate purposes.
Is the Manipal Health Enterprises IPO expensive?
Yes. At the upper price band, the IPO is valued at approximately 145 times FY25 earnings and around 121 times annualised H1 FY26 earnings. The valuation is demanding despite the company’s strong business quality.
What are the major risks in the Manipal Health Enterprises IPO?
Key risks include expensive valuation, capital-intensive operations, dependence on doctors, integration risk from acquisitions, healthcare regulation and the possibility of slower-than-expected improvement in profitability.
Should investors apply for the Manipal Health Enterprises IPO?
Chanakya’s current recommendation is Selective Apply. Listing-gain investors should track GMP and QIB subscription, while long-term investors should consider the high valuation before applying.
Summary
Manipal Health Enterprises is launching an approximately Rs. 9,210–9,275 crore mainboard IPO at a price band of Rs. 560–590 per share. The company operates one of India’s largest multispecialty hospital networks and has a strong presence in Bengaluru, Kolkata and Pune.
The fresh issue proceeds will primarily reduce debt and finance the acquisition of a minority stake in Sahyadri Hospitals. This could improve the balance sheet and strengthen future profit growth. However, the issue is valued at a substantial premium based on reported earnings.
The company offers strong business quality and favourable long-term prospects, but the valuation leaves a limited margin of safety. Chanakya’s recommendation is Selective Apply, subject to GMP, QIB participation and market sentiment.